Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory…
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Dr Hugo Villanueva is to join as Innovation and Business Development Director in May 2020.
Hugo joins us from Revenant Bio, a research organisation and consultancy supporting and attracting funding for start-ups, spinouts and growing companies in the life sciences sector and has experience of working with Clustermarket.
He is passionate about life science entrepreneurship and the commercialisation of research. As a founding member of the…
AMSBIO offer a trio of sterilization systems suitable for a range of applications from sterilizing small laboratory instruments to sterilizing large research facilities.These compact sterilizers use a mixture of ozone and UV to kill pathogenic organisms, including viruses, bacteria, and fungi. Ozone scrubbing technology enables the devices to convert ozone gas back to oxygen, giving you maximum protection against pathogens with minimum effort and zero risk.The CoolCLAVE™ Plus is a unique and innovative laboratory bench top sterilizer that is highly effective in keeping sterile, or…
London, UK, 20th April 2020 / Sciad Newswire / MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels. The Company will develop its novel cell bioprocessing technology, utilising microfluidics to tackle the challenges associated with bioprocessing for cell and gene therapy.
MicrofluidX leverages the power of microfluidics to overcome the challenges of bioprocessing in the production of cell and gene therapies…
By George Underwood
April 9, 2020
Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.
In fact, they are engaging with digital education platforms more than ever before, suggesting that these channels could fill the gaps now left in pharma’s marketing programmes.
As one of the largest providers of medical information for physicians, Medscape has found itself at the forefront of informing healthcare professionals around the world on COVID-19.
“We’ve…
Colmar, PA – April 15, 2020 – Biological Specialty Company (BSC), a BioIVT company, has launched an at-home blood donation service for COVID-19 positive patients. Blood donations are urgently required from patients who are sick with or have recovered from COVID-19 to help develop new therapies, vaccines and diagnostic biomarkers for the disease. BSC is a critical service supplying more than 30,000 pharma, biotech, diagnostic and government researchers with human blood products for scientific research.
“It is critically important that the scientific community has access to COVID-19…
Oxford, UK, 15th April 2020 / Sciad Newswire / The Covid-19 Volunteer Testing Network launched on 1st April 2020 to provide essential additional testing capacity to front-line workers. The project, started by Mike Fischer CBE, helps small laboratories convert to run critical antigen testing and identify Covid-19 cases among local healthcare workers - at no cost to Government.
The UK has thousands of small laboratories with the right equipment, personnel and processes to run Covid-19 testing. Although some of the critical RT-PCR machines in university and…
Responding to an increase in demand for its expert regulatory services, leading pharmaceutical and biotech product development consultancy Boyds has made two key hires to its Regulatory Affairs team.
Dr Victoria Marsh joins the company as Director of Regulatory Affairs and Dr Kim Champion as Regulatory Affairs Manager.
A specialist in molecular biology and protein biochemistry, Victoria has extensive regulatory experience across the full clinical product lifecycle from Phase 1 clinical trials through to licence maintenance for marketed products. She has worked with and for companies…
Cambridge UK – 15 April 2020 – Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).
NF is a rare genetic disorder that affects 1 in 3,000 people worldwide. Currently, no treatments exist for any of the three types of NF (NF1, NF2 and schwannomatosis). Healx will combine its AI technology and drug discovery expertise with the disease data,…
Cambridge, UK, 14 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS…